saikogenin E | 13715-23-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: saikogenin E
• 英文别名: (1S,2S,4S,5R,8R,10S,13S,14R,17S,18R)-4,5,9,9,13,20,20-heptamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-ene-2,10-diol
• CAS: 13715-23-6
• 化学式: C₃₀H₄₈O₃
• 分子量: 456.709
• InChiKey: IUXCCCANLLMMGX-KTLSIJAESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  33
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 saikogenin E 在 对甲苯磺酸 作用下， 生成 11-Methoxy-Δ¹²-oleanen-3β,16β,28-triol
  参考文献：
  名称：

  The Chemical Studies on Oriental Plant Drugs. XVIII. The Constituents of Bupleurum spp. (3). Saikogenins E and G

  摘要：

  A genuine sapogenin, saikogenin E, was isolated by applying the Smith-type controled degradation procedure for saikoside II fraction, one of the main saponins of Bupleurum falcatum L. It was also obtained by alkaline degradation of the periodate oxidized saponin. The structure of saikogenin E (Ia) was elucidated and saikogenins B and C were proved to be the artifacts derived from it. Saikogenin G, the genuine sapogenin corresponding to saikogenin D, was also obtained by modified de Mayo-type degradation method and its structure was established as (Va).

  DOI：

  10.1248/cpb.16.641
• 作为产物：
  描述：

  柴胡皂苷C 在 mouse intestinal flora 作用下， 以 乙醇 为溶剂， 反应 12.0h， 以12 mg的产率得到saikogenin E
  参考文献：
  名称：

  New derivatives of saikosaponins.

  摘要：

  在对柴胡皂苷（柴胡的主要成分）的新陈代谢进行研究的过程中，在用酸和蜗牛酶进行培养后，分离出了五种新的化合物，它们分别来自柴胡皂苷a、c和d。在1 N硫酸-二氧六环溶液中，将柴胡皂苷a和c在60°C下培养，分离出了柴胡皂苷g和i，它们在C-9（11）、12处具有同环二烯部分，其结构被确定为3β，16β，23，28-四羟基齐墩果-9（11），12-二烯3-O-β-D-吡喃葡萄糖基（1→3）-β-D-吡喃岩藻糖苷和3β，16β，28-三羟基齐墩果-9（11），12-二烯3-O-β-D-吡喃葡萄糖基（1→6）-[α-L-吡喃鼠李糖基（1→4）] -β-D-吡喃葡萄糖苷。此外，在37°C下用蜗牛酶将柴胡皂苷b1、g和b2培养12小时后，形成了原柴胡皂�

  DOI：

  10.1248/cpb.33.3349

文献信息

• EXTRACELLULAR MATRIX PRODUCTION PROMOTER
  申请人：SHISEIDO COMPANY LIMITED

  公开号：EP0972508A1

  公开（公告）日：2000-01-19

  An agent which promotes the production of extracellular matrix; more particularly, acidic mucopolysaccharides such as hyaluronic acid and fibrous proteins such as collagen, and thus exhibits the effects of activating the extracellular matrix, normalizing skin tissue, and efficiently preventing skin aging by reinforcing the binding between the epidermis and the dermis. This agent contains as active ingredients the extracts of plants belonging to the genus Bupleurum such as B. falcatum Linne (Mishima Saiko), or saikosaponin and saikogenin contained in these extracts. Use of this agent as a skin preparation for external use, etc. makes it possible to promote the production of the above acidic mucosaccharides, fibrous proteins, etc. in fibroblasts, etc.

  一种促进细胞外基质生成的制剂，尤其是酸性粘多糖（如透明质酸）和纤维蛋白（如胶原蛋白），因此具有激活细胞外基质、使皮肤组织正常化以及通过加强表皮和真皮之间的结合有效防止皮肤老化的功效。本制剂的有效成分包括 Bupleurum（如 B. falcatum Linne（三岛茜草））属植物的提取物，或这些提取物中的 saikosaponin 和 saikogenin。将这种制剂用作外用皮肤制剂等，可促进成纤维细胞等产生上述酸性粘多糖、纤维蛋白等。
• Polynucleotide binding complexes comprising sterols and saponin
  申请人：Nordic Vaccine Technology A/S

  公开号：EP2011517A1

  公开（公告）日：2009-01-07

  The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.

  本发明涉及由甾醇和皂甙组成的复合物。这些复合物能够结合包括多核苷酸在内的遗传决定因子。复合物可进一步包含亲脂分子，可选择包含接触基团和/或靶向配体的亲脂分子和/或糖分子。复合物可进一步包括免疫原决定簇和/或抗原决定簇和/或药物和/或诊断化合物。在更进一步的实施方案中，复合物可被包括生物可降解微球在内的封装剂封装。本发明还涉及通过治疗和/或手术对个体进行治疗的药物组合物和方法、美容治疗方法以及对人体或动物体进行诊断的方法。
• POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS
  申请人：Nordic Vaccine Technology A/S

  公开号：EP1377320B1

  公开（公告）日：2008-10-01
• THERAPEUTICAL VACCINATION
  申请人：Nordic Vaccine Technology A/S

  公开号：EP1409009A1

  公开（公告）日：2004-04-21
• PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS
  申请人：DALSGAARD Kristian

  公开号：US20110020226A1

  公开（公告）日：2011-01-27

  The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.